Incorporating scores from two urine-based biomarker assays may reduce the number of biopsies men with clinically localized prostate cancer need to undergo without greatly affecting 10-year survival rates, according to the results of a decision analysis. Read the article.
Urine biomarkers may reduce repeat biopsies for prostate cancer Read More »
Scientists at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have shown that the cells responsible for generating deadly prostate cancer share some genetic qualities with the tissue-specific stem cells that naturally reside in the healthy prostate. Read the article.
UCLA-led study shows deadly prostate cancer cells have stem cell qualities Read More »
Continuation of androgen deprivation therapy for an additional 24 months improves all disease end points during 15 years of follow-up compared with short-term androgen deprivation in men with locally advanced prostate cancer treated with radiotherapy. Read the article.
Long-term ADT Best for Locally Advanced Prostate Cancer Read More »
The addition of hormonal therapy to salvage radiotherapy demonstrated a significant survival benefit in patients with prostate cancer recurrence after radical prostatectomy, according to long-term follow-up data from a randomized trial. Read the article.
Combining Radiotherapy With Anti-Androgen Improves Prostate Cancer Survival Read More »
Men with prostate cancer who also have had a heart attack may fare better with radiation therapy alone rather than with the standard treatment of radiation plus hormone therapy, a new analysis suggests. Over an average of 17 years of follow-up, men with high-risk prostate cancer who also had a heart condition lived longer after radiation treatment alone than similar men who had radiation and hormone therapy. Men who didn’t have heart problems lived longer if they had both treatments, the researchers added. Read the article.
Some Prostate Cancer Patients May Not Benefit From Hormone Therapy Read More »
A revolutionary prostate biopsy approach uses fewer needles and is more accurate for diagnosing prostate cancer. It is done during a real time MRI (magnetic resonance imaging) scan that clearly shows suspicious sites. When done by an expert radiologist using a highly powerful magnet, only a minimum number of needles are used to sample suspicious abnormalities. Read the article.
Revolutionary prostate biopsy approach more accurate at diagnosing prostate cancer Read More »
The study provides compelling evidence that few benign cancer suspicious regions increase in suspicion score and/or the greatest linear measurement within 1 year independent of the baseline suspicion score. Therefore, routinely repeating multiparametric magnetic resonance imaging at 1 year in men with pathologically benign cancer suspicious regions should be discouraged since it is unlikely to influence management decisions. Read the article.
High-dose-rate (HDR) brachytherapy was originally used with external beam radiation therapy (EBRT) to increase the dose to the prostate without injuring the bladder or rectum. Numerous studies have reported HDR brachytherapy is safe and effective. It has been adapted for use without EBRT for cases not requiring lymph node treatment. Read the article.
High-dose-rate brachytherapy (HDRBT) monotherapy — 10 year results Read More »
Delaying surgery does not appear to harm men on active surveillance (AS) for prostate cancer (PCa), a new study finds. Over 3 years after radical surgery, men who delayed surgery and those who had immediate surgery had similar rates of biochemical recurrence. Read the article.
Delaying RP with Active Surveillance Carries No Greater Risks Read More »
PSA production may be lower in African-American than Caucasian men with low-risk prostate cancer (PCa), a new study suggests. If confirmed, the finding could impact active surveillance criteria for black patients. Read the article.
Black Men with Low-Risk Prostate Cancer Produce Less PSA Read More »